GEN Exclusives

More »

GEN News Highlights

Back to Item »

Novartis Pays Incyte $50M on Start of Phase III Trial with INCB18424 for Polycythemia Vera

JAK1/2 inhibitor is in joint Phase II/III development against multiple disorders.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

The Uproar over Fetal Tissue Donations

Does your academic or industry lab use fetal tissue in its research?

More »